Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Per-Anders Abrahamsson

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
Asian Journal of Urology|February 2, 2018
Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dotsPer-Anders Abrahamsson
European Urology|August 18, 2009
Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literaturePer-Anders Abrahamsson
Frontiers of Radiation Therapy and Oncology|June 12, 2008
Prostate cancer and active surveillancePer-Anders Abrahamsson
The Journal of Urology|January 25, 2003
Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancerGuram Karazanashvili, Per-Anders Abrahamsson
European Urology|January 22, 2005
Neuroendocrine differentiation in prostate cancer: implications for new treatment modalitiesNadezda Vashchenko, Per-Anders Abrahamsson
Scandinavian Journal of Urology and Nephrology. Supplementum|July 5, 2003
Neuroendocrine differentiation in prostatic carcinomaJens Hansson, Per-Anders Abrahamsson
European Urology|June 17, 2008
PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?E David Crawford, Per-Anders Abrahamsson
Asian Journal of Andrology|July 14, 2020
Androgen deprivation therapy and side effects: are GnRH antagonists safer?Stephen J Freedland, Per-Anders Abrahamsson
International Journal of Urology : Official Journal of the Japanese Urological Association|July 15, 2020
Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancerHendrik Van Poppel, Per-Anders Abrahamsson
Anticancer Research|April 12, 2012
Expression of serotonin receptors 5-HT1A, 5-HT1B, 5-HT2B and 5-HT4 in ovary and in ovarian tumoursRudi Henriksen, Nishtman Dizeyi, Per-Anders Abrahamsson
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Asian Journal of Urology|February 2, 2018
Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dotsPer-Anders Abrahamsson
European Urology|August 18, 2009
Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literaturePer-Anders Abrahamsson
Frontiers of Radiation Therapy and Oncology|June 12, 2008
Prostate cancer and active surveillancePer-Anders Abrahamsson
The Journal of Urology|January 25, 2003
Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancerGuram Karazanashvili, Per-Anders Abrahamsson
European Urology|January 22, 2005
Neuroendocrine differentiation in prostate cancer: implications for new treatment modalitiesNadezda Vashchenko, Per-Anders Abrahamsson
Scandinavian Journal of Urology and Nephrology. Supplementum|July 5, 2003
Neuroendocrine differentiation in prostatic carcinomaJens Hansson, Per-Anders Abrahamsson
European Urology|June 17, 2008
PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?E David Crawford, Per-Anders Abrahamsson
Asian Journal of Andrology|July 14, 2020
Androgen deprivation therapy and side effects: are GnRH antagonists safer?Stephen J Freedland, Per-Anders Abrahamsson
International Journal of Urology : Official Journal of the Japanese Urological Association|July 15, 2020
Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancerHendrik Van Poppel, Per-Anders Abrahamsson
Anticancer Research|April 12, 2012
Expression of serotonin receptors 5-HT1A, 5-HT1B, 5-HT2B and 5-HT4 in ovary and in ovarian tumoursRudi Henriksen, Nishtman Dizeyi, Per-Anders Abrahamsson
Pageof 6